Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007

Wednesday, February 6, 2008 General News J E 4
PITTSBURGH, Feb. 5 Mylan Inc. (NYSE: MYL)announced today that it will host a conference call and live webcast onWednesday, Feb. 27, 2008, at 10:30 a.m. ET to provide a review of the quarterand nine months ended Dec. 31, 2007. The Company also will provide anoperational and integration update on Merck Generics, which the Companyacquired on Oct. 2, 2007. The Company will release its financial resultsbefore the market opens.

The Company also announced that it will be presenting at the Merrill LynchGlobal Pharmaceutical, Biotechnology and Medical Device Conference today, Feb.5, at 11:40 a.m. ET. A copy of the Company's slide presentation will beavailable at

The dial-in number to access the Feb. 27 call is 877-874-1586 or 719-325-4814 for international callers. A replay, available for approximately eightdays, will be available at 888-203-1112 or 719-457-0820 for internationalcallers, with access pass code 8774583.

To access a live webcast of the Feb. 27 call, please log on to Mylan's Website ( at least 15 minutes before the event is to begin toregister and download or install any necessary software. A replay of thewebcast will be available on for approximately eight days.

Mylan Inc. is one of the world's leading quality generic and specialtypharmaceutical companies. The Company offers one of the industry's broadestand highest quality product portfolios, a robust product pipeline and a globalcommercial footprint through operations in more than 90 countries. Through itscontrolling interest in Matrix Laboratories Limited, Mylan has direct accessto one of the largest active pharmaceutical ingredient (API) manufacturers inthe world. Dey L.P., Mylan's fully integrated specialty business, provides theCompany with innovative and diversified opportunities in the respiratory andallergy therapeutic areas.

For more information about Mylan, visit

SOURCE Mylan Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Intrasphere Technologies Releases PharmaCM Submiss...
Flurizan's Effect in Delaying Progression From Mil...